Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088908 | 1.00 | CA2 (0.55) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL28885652 | 0.98 | CA2 (0.53) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL28322896 | 0.98 | CA2 (0.53) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL28885660 | 0.98 | CA2 (0.53) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL28322897 | 0.98 | CA2 (0.53) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL28323960 | 0.98 | CA2 (0.53) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL16124694 | 0.89 | EPHX2 (0.60) | CA2CA4EPHX2NOD1GNPAT | |
| SCHEMBL13674348 | 0.87 | CA2 (0.62) | CA2CA4EPHX2NOD1CASP3 | |
| SCHEMBL7218630 | 0.87 | EPHX2 (0.67) | CA2CA4EPHX2NOD1 | |
| SCHEMBL7218627 | 0.87 | EPHX2 (0.67) | CA2CA4EPHX2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118488855-A | Solid composition comprising peptide or protein and acylated amino acid | 阿道恰公司 | 2024-08-13 | — | — | CN | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | disclosed |
| CN-110325052-B | Application of aspartic acid fatty acyl derivative in preparation of animal feed additive | 彭险峰 | 2022-11-18 | — | — | CN | disclosed |
| CN-110325052-A | Asparatate fatty acyl group derivative is preparing the application in animal feed additive | 黄华成 | 2019-10-11 | — | — | CN | disclosed |
| US-8415328-B2 | Factor VIIa inhibitor | PHARMACYCLICS, INC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | CA2 398/4885CA4 445/4885EPHX2 4600/4885 |
| US-20110207939-A1 | FACTOR VIIA INHIBITOR | F7, F9, F5 | CA2 3556/4885CA4 2395/4885EPHX2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.